Active, not recruitingPhase 3NCT05515536
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
Studying Friedreich ataxia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PTC Therapeutics
- Intervention
- Vatiquinone(drug)
- Enrollment
- 130 enrolled
- Eligibility
- All sexes
- Timeline
- 2022 – 2027
Study locations (14)
- UCLA, Los Angeles, California, United States
- University of Florida, Gainesville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Murdoch Children's Research Institute, Parkville, Victoria, Australia
- University of Campinas (UNICAMP) - School of Medical Sciences, Dept of Neurology, São Paulo, Brazil
- Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM), Montreal, Quebec, Canada
- CHU Sainte-Justine, Montreal, Quebec, Canada
- Hôpital Pitié-Salpêtrière, Institut du Cerveau (Paris Brain Institute), Paris, France
- Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany
- Ospedale Pediatrico Bambino Gesu' IRCCS, Roma, Italy
- CBR Neurogenetic Research Clinic, University of Auckland, Auckland, New Zealand
- Hospital Sant Joan de Déu Barcelona Unidad de Enfermedades Neuromusculares, Barcelona, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05515536 on ClinicalTrials.govOther trials for Friedreich ataxia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06628687A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their BabiesBiogen
- RECRUITINGNCT06865482Clinical Course Of Disease In Participants With FA-CMLexeo Therapeutics
- RECRUITINGPHASE3NCT06953583A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)Biogen
- RECRUITINGPHASE1, PHASE2NCT06874010A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's AtaxiaDesign Therapeutics, Inc.
- RECRUITINGNCT07013292Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's AtaxiaCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT06692296Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's AtaxiaIRCCS Eugenio Medea
- RECRUITINGNCT06623890A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own DoctorsBiogen
- RECRUITINGPHASE1NCT06054893A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldBiogen